References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/2079-701X-2013-4-36-41

medsovet-982

Research Article

НЕРВНО-ПСИХИЧЕСКИЕ РАССТРОЙСТВА

NEUROPSYCHIATRIC DISORDERS

Депрессия при болезни Паркинсона как ведущий фактор ухудшения качества жизни пациентов: пато физиология, диагностика, терапия

Depression in Parkinson's disease as the key factor of deterioration in quality of life: pathophysiology, diagnostics and treatment

Нодель

М. Р.

Nodel

M. R.

noemail@neicon.ru

Первый МГМУ им. И.М. Сеченова, МоскваРоссияthe First Moscow State Medical University named after I.M.SechenovRussian Federation

2013

30122013

043641

2013

Нодель М.Р.

Nodel M.R.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/982

Болезнь Паркинсона (БП) – мультисистемное нейродегенеративное заболевание с широким спектром не только двигательных, но и нервно-психических нарушений. Депрессия встречается в среднем у 40–50% пациентов с болезнью Паркинсона и является одним из ведущих факторов, снижающих качество жизни. В статье представлены современные представления о клинике, патофизиологии и подходах к терапии депрессии при болезни Паркинсона.

Parkinson's disease (PD) is multisystem neurodegenerative disorder with a wide range of motor, nervous and mental disorders. On average, depression occurs in 40-50% of patients with Parkinson's disease and is a major factors of deterioration of life quality. The article tells about present-day knowledge about the disease pattern, pathophysiology and approaches to the treatment of depression in Parkinson's disease.

болезнь ПаркинсонадепрессияклиникапатофизиологиядиагностикатерапияParkinson's diseasedepressiondisease patternpathophysiologydiagnosticstherapy

References1

Яхно Н.Н. Невропсихиатрия. Место неврологов. X Всероссийский съезд неврологов с международным участием // Материалы съезда. Н. Новгород, 2012. С. 698.

Яхно Н.Н. Захаров В.В., Нодель М.Р. Когнитивные и другие нервно-психические нарушения болезни Паркинсона // Болезни движений: медицинские и социальные аспекты / под ред. Е.И. Гусева, А.Б. Гехт. М., 2010. С. 95–97.

Нодель М.Р., Яхно Н.Н. Нервно-психические нарушения болезни Паркинсона // Неврология. Нейропсихиатрия. Психосоматика. 2009. №2. C. 3–8.

Нодель М.Р. Недвигательные нарушения болезни Паркинсона // Доктор.Ру. Неврология. 2009. №4. C. 12–16.

Левин О.С. Болезнь Паркинсона как нейропсихиатрическое заболевание: Руководство для врачей по материалам II Национального конгресса по болезни Паркинсона и расстройствам движений / под ред. С.Н. Иллариошкина, О.С. Левина. М., 2011. С. 99–104.

Нодель М.Р. Клинические особенности и лечение недвигательных нарушений болезни Паркинсона // Медицинский совет. 2012. №4. С. 30–36.

Aarsland D., Marsh L., Schrag А. Neuropsychiatric symptoms in Parkinsons Disease // Mov.Dis. 2009. Vol. 24(15). P. 2175–86.

O’Sullivan S.S., Williams D.R., Gallarher D.A. et al. Non motor symptoms as presenting complaints in Parkinsons disease: a clinicopathological study // Mov. Dis. 2008. Vol. 23. P. 101–106.

Shrag A., Jahanshahi M., Quinn N.P. What contributes to quality life in patients with Parkinsons disease? // J. Neurol. Neurosurg. Neuropsych. 2000. Vol. 69. P. 308–312.

Scaravilli T., Gasparoli E., Rinaldi F. et al. Health related quality of life in Parkinsons disease // J. Nourol. Neurosurg. Psychiat. 2003. №74 (2). P. 163–169.

McKinlay A., Grace R.C., Dalrymple-Alford J.C. et al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinsons disease // Park. and Relat. disord. 2008. Vol. 14. P. 37–42

Cole S.A., Woodard J.L., Juncos J.L. et al. Depression and disability in Parkinsons disease // J. Neuropsychiatry Clin. Neurosci. 1996. Vol. 8. P. 20–25.

Shrag A., Jahanshahi M., Quinn N.P. What contributes to depression in Parkinsons disease? // Psychol. Med. 2001. Vol. 31. P. 65–73.

Starkstein S.E., Preziosi T.J., Robinson R.G. Sleep disorders, pain and Parkinsons disease depression in Parkinsons disease // Eur. Neurol. 1991. Vol. 31(6). P. 352–355.

Norman S., Troster A.I., Fields J.A. et al. Effects of depression and Parkinsons disease on cognitive functioning // J. Neuropsychiatr. Clin. Neurosci. 2002. Vol. 14(1). P. 31–36.

Нодель М.Р. Депрессия при болезни Паркинсона // Неврология. Нейропсихиатрия. Психосоматика. 2010. №4. C. 11–17. Полный список литературы вы можете запросить в редакции.

Левин О.С. Болезнь Паркинсона как нейропсихиатрическое заболевание. //Руководство для врачей по материалам II Национального конгресса по болезни Паркинсона и расстройствам движений (под ред. С.Н. Иллариошкина, О.С. Левина). М. 2011. С.99–104.

М.Р. Нодель. Клинические особенности и лечение недвигательных нарушений болезни Паркинсона.// Медицинский совет. -2012.-N 4.-С.30-36.

D.Aarsland, Marsh L., A.Schrag . Neuropsychiatric symptoms in Parkinsons Disease. //Mov.Dis.-2009- Vol.24(15).-P.2175-86.

OSullivan S.S., Williams D.R., Gallarher D.A., et,.al. Non motor symptoms as presenting complaints in Parkinsons disease: a clinicopathological study. //Mov.Dis.-2008-Vol.23-P.101-106.

Shrag A., Jahanshahi M., Quinn N.P. What contributes to quality life in patients with Parkinsons disease?//J.Neurol.Neurosurg.Neuropsych.-2000.-Vol.69.-P.308-312.

Scaravilli T., Gasparoli E., Rinaldi F. et.al. Health related quality of life in Parkinsons disease. // J.Nourol.Neurosurg.Psychiat.-2003.-74 (2)-P.163-169.

Mc Kinlay A., Grace R.C., Dalrymple-Alford J.C., et.al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinsons disease. //Park. and Relat. disord.-2008.-Vol.14.-P.37-42

Cole S. A., Woodard J. L. , Juncos J. L. , et. al. Depression and disability in Parkinsons disease. // J. Neuropsychiatry Clin. Neurosci. -1996. - Vol. 8. - P. 20-25.

Shrag A., Jahanshahi M., Quinn N.P. What contributes to depression in Parkinsons disease?// Psychol.Med.-2001.-Vol.31.-P.65-73.

S.E.Starkstein, Preziosi T.J., Robinson R.G. Sleep disorders, pain and Parkinsons disease depression in Parkinsons disease. //Eur. Neurol.-1991.-Vol.31(6).-P.352-355.

Norman S., Troster A.I., Fields J.A., et.al. Effects of depression and Parkinsons disease on cognitive functioning. . // J.Neuropsychiatr.Clin. Neurosci.-2002.-Vol.14(1).-P.31-36.

М.Р. Нодель. Депрессия при болезни Паркинсона. //Неврология.

Нейропсихиатрия.Психосоматика.-2010.-N4.- C.11-17.

Dooneief G., Mirabello E., Bell K., et.al. An estimate of the incidence of depression in idiopathic Parkinsons disease. //Arch.Neurol.-1992.-Vol.49(3).-P.305-307.

Lemke M.R. Depressive symptoms in Parkinsons disease. //Eur. J.of Neurol.-2008.-Vol.15(Suppl.1).-P.21-25.

Gotham A. M., Brown R. C. , Marsden C. D. Depression in Parkinsons disease: a quantitative and qualitative analysis in Parkinsons disease. // J. Neuropsychiatry Clin. Neurosci. -1996. - Vol. 8. - P. 20-25.

Mayberg H.S., Starkstein S.E., Sadzot B., et.al. Selective hypometaboloism in the inferior frontal lobe in depressed patients with Parkinsons Disease. //Ann.Neurol.-1990.-Vol.28(1)-P.57-64.

Matsiu H., Nishinaka K., Oda M., et.al. Depression in Parkinsons disease:diffusion tensor imaging study. //J.Neurol.-2007.-Vol.254.-P.1170-1173.

Chaudhuri K.R., Schapira A. H.V. Non-motor symptoms of Parkinsons disease: dopaminergic pathophysiology 23. R.Mayeux, Y.Stern, I.Cote , J.B. Williams. Altered serotonin metabolism in depressed patients with Parkinsons Disease. //Neurol.-1984.-Vol.34(5).-P.642-646.

M.Yamomoto. Depression in Parkinsons Disease : its prevalence, diagnosis, and neurochemical background. //J.Neurol.-2001.-Vol.248 (Suppl

P.G.Frisina, V.Haroutunian, L.S.Libow. The neuropatological basis for depression in Parkinsons Disease. //Park. and Relat.Dis.-2009.-Vol.15.-P.144-148.

Remy P., M.Doder, A.Lees, et.al. Depression in Parkinsons Disease: loss of dopamine and noradrenaline innervation in the limbic system. //Brain.-2005.-Vol.128.-P.1314-1322.

M.Guttman, M.Torti, J.Warsh et.al. Are brain serotonin transporter levels decreased in depressed patients with Parkinsons Disease? //J.Neurol.Sci-2006.-Vol.248-P.299.

Alex K.D., Pehek E.A. Pharmacologic mechanisms of serotoninergic regulation of dopamine neurotransmission. // Pharmacol. Ther.-2007.-Vol.113-P.296-320.

F.Fang, Q.Xu, Y.Park, X.Huang, et.al. Depression and the subsequent risk of Parkinsons disease in the NIN-AARP Diet and Health Study. //Mov.Dis.-2010-Vol.25.-N9.-P.1157-1162.

Braak H., Del Tredici K., Rub U., et. al. Staging of brain pathology related to sporadic Parkinsons disease. //Neurology Aging - 2003.-Vol.24.-P.197-210.

Santamaria J. , Tolosa E. , Valles A. Parkinsons disease with depression: a possible subgroup of idiopathic parkinsonism. //Neurology. -1986. - Vol. 36. - P. 1130-1133.

A.F.Leentjens, R.Lousberg, F.R.Verhey. Markers for depression in Parkinsons Disease. //Acta Psych.Scand.-2002.-Vol.106(3)-P.196-201.

Cummings J. L. Depression and Parkinsons disease: a review. // Am. J. Psychiatry-1992. - Vol. 149. - P. 443-454.

E.Tanberg, J.P.Larsen, D.Aarsland et.al. Risk factors for depression in Parkinsons Disease. //Arch. Neurol.-1997.-Vol.54(5).-P.625-630.

A.Rojo , M.Agullar , M.T. Garolera , et.al. Depression and Parkinsons disease: clinical correlates and outcome. //Park. Relat Dis.- 2003.-Vol.10(1).-P.23-28.

Cole S.A., Woodard J.L., Juncos J.L., et.al. Depression and disability in Parkinsons disease. //J.Neuropsychiatr.Clin. Neurosci-1996.-Vol.8(1).-P.20-25.

C.Becker, G.P.Brobert, S.Johansson et.al. Risk of incident depression in patients with Parkinsons disease in the UK. //Eur.J.of Neurol.-2011.-Vol.18.-P.448-453.

A.Althaus, O.A.Becker, A.Spottke, et.al. Frequency and treatment of depressive symptoms in a Parkinsons Disease registry. //Park. and Relat. disord.-2008.-Vol.14.-P.626-632

Y.Cheng, C.Liu, C.Mao et.al. Social support plays a role in depression in Parkinsons disease: a cross-section study in a Chinese cohort. //Park. аnd Related Dis.-2008.-Vol.14.-P.43-45.

Янакаева Т. А. Сравнительный анализ когнитивных и аффективных расстройств при дисциркуляторной энцефалопатии, болезни Паркинсона и болезни Альцгеймера. Диссертация …канд. мед. наук. – М., 1999.

E.Starkstein, Petracca G., Chemerinski E., et.al. Depression in classic versus akinetic-rigid Parkinsons disease. //J.Neur. Ment.Dis.-1998.-Vol.13(1).P.-29-33.

F.Liebermann. Depression in Parkinsons Disease- a review. //Acta Neurol.Scand.-2006.-Vol.113-P.1-8.

Lemke M.R. Depressive symptoms in Parkinsons disease. //Eur.J.of Neurol.-2008.-Vol.15(Suppl.1).-P.21-25.

American Psychiatric Association. Diagnostic and Statistical Manual of mental Disorders, 4-th ed. Washington, ВС:APA Press 2000.

J.Reiff, N.Schmidt, B.Riebe, et.al. Subthreshold depression in Parkinsons disease. //Mov.Dis.-2011-Vol.26-N9.-P.1741-1744.

S.E.Starkstein , M.Merello, R.Jorge , et.al. A validity study of depressive syndromes in Parkinsons disease. // Mov.Dis.-2008-Vol.23-P.538-546.

T.Inoue, M.Kitagawa, T.Tanaka, et.al. Depression and major depressive disorder in patients with Parkinsons disease. // Mov.Dis.-2010-Vol.25-N1-P.44-49.

Barone P., Antonini A., Colosimo C., et.al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson disease. //Mov.Dis.-2009.-Jun 9.-P.215-216.

Shrag A., Barone P., Brown R.G. et.al. Depression rating scales in Parkinson disease: critique and recommendations. //Mov.Dis.-2007.-Vol.22.-P.1077-1192.

Dujardin K., Sockeel P., Devos D., et.al. Characteristic of apathy in Parkinsons disease. // Mov.Dis.-2007.-Vol.22.-P.778-784.

М.Р. Нодель. Утомляемость при болезни Паркинсона и ее коррекция агонистом дофаминовых рецепторов прамипексолом //Неврология. Нейропсихиатрия.Психосоматика.-2011.-N 4.- C.22-26.

Barone P et al. Depression and antidepressant use in Parkinson’s disease: Results from the PRODEST-PD study. Abstract P1122 poster presented at 11th Congress of EFNS, Brussels, 26 Aug 2007.

Weintraub D., Morales K.H., Moberg P.J., et.al. Antidepressant studies in Parkinsons disease: a review and meta-analysis. // Mov.Dis.-2005.-Vol.20.-P.1161-1169.

Miyasaki J.M., Shannon K., Voon V., et.al. Practice parameter: evaluation and treatment of depression, psychosis and dementia in Parkinsons disease (an evidence-based review):report of the Quality Standards Subcommittee of the American Academy of Neurology. //Neurol.-2006.-Vol.66.-P.996-1002.

Devos D., Dujardin K., Poirot I., et.al. Comparison of desipramine and citalopram treatments with depression in Parkinsons disease: a double-blind placebo-controlled study. //Mov.Dis.-2008.-Vol.23.-P.850-7.

I.H.Richard, M.P.McDermott, R.Kurlan et.al. A randomized, double –blind, placebo-controlled trial of antidepressants in Parkinsons disease. //Neurol.-2012-Vol.11-N9.-P.26-34.

Menza M., Dobkin R.D., Marin H., et.al. A controlled trial of antidepressants in patients with Parkinsons disease and depression. //Neurol.-2009.-Vol.72.-P.886-92

Mann J. J., Kapur S. A dopaminergic hypothesis of major depression. // Clin. Neuropharmacol. -1996. -Vol. 18(suppl. 1). -P. 57-65.

Barbeu A. L. L-Dopa therapy in Parkinson disease: a critical review of nine years experience. // J. Can. Med. Assoc. -1969. -Vol. 101. -P. 791-800.

Нодель М.Р., Артемьев Д.В., Яхно Н.Н.. Эффективность дофаминового агониста Мирапекса при болезни Паркинсона. // Неврологический журнал. - 1999. – N6. - С. 45-49.

Левин О.С., Федорова Н.В., Смоленцева И.Г. Применение агонистов дофаминовых рецепторов при болезни Паркинсона.//Неврологический журнал- 2002. -№1. С.41-45.

Lemke M.P., Brecht H.M., Koester J.K., et.al. Anhedonia, depression, and motor functioning in Parkinsons disease during treatment with Pramipexole. //J.Neuropsych.Clin.Neurosci-2005.-Vol.17.-P.2.-P.214-220.

Barone P., Poewe W., Tolosa E., et.al. Efficacy of double-blind, placebo-controlled pramipexole against depression in Parkinsons disease. Abstracts of the Movement Disorders Societys Thirteenth International Congress of Parkinson's disease and movement disorders. June 7-11-2009-Suppl.1 –P.291.

Schoenfeld M.A., Pantelie C.M., B. Schwartz . Clinical criteria for the switch of treatment strategies in Parkinson’s disease. //Clinical Neurol. and Neurosurg. -2003.-Vol. 105.-P.241-244.

The authors declare that there are no conflicts of interest present.